Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 300 entries
Sorted by: Best Match Show Resources per page
The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.

Multiple sclerosis and related disorders

Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, Gustafson T, Cutter GR, Wolinsky JS, Lublin FD.
PMID: 25876935
Mult Scler Relat Disord. 2012 Apr;1(2):81-6. doi: 10.1016/j.msard.2012.01.006. Epub 2012 Feb 23.

BACKGROUND: Interferon-β1a (IFNB) and glatiramer acetate (GA) are distinct therapies which are both partially effective for relapsing MS. It is not known if combining the two treatments would be more effective.OBJECTIVE: To review the rationale, design, and baseline characteristics...

Cite
Lindsey JW, Scott TF, Lynch SG, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord. 2012;1(2):81-6doi: 10.1016/j.msard.2012.01.006.
Lindsey, J. W., Scott, T. F., Lynch, S. G., Cofield, S. S., Nelson, F., Conwit, R., Gustafson, T., Cutter, G. R., Wolinsky, J. S., Lublin, F. D. (2012). The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Multiple sclerosis and related disorders, 1(2), 81-6. https://doi.org/10.1016/j.msard.2012.01.006
Lindsey, J W, et al. "The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics." Multiple sclerosis and related disorders vol. 1,2 (2012): 81-6. doi: https://doi.org/10.1016/j.msard.2012.01.006
Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, Gustafson T, Cutter GR, Wolinsky JS, Lublin FD. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord. 2012 Apr;1(2):81-6. doi: 10.1016/j.msard.2012.01.006. Epub 2012 Feb 23. PMID: 25876935.
Copy Download .nbib Format: NLM
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

Multiple sclerosis and related disorders

Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA.
PMID: 25876473
Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12.

BACKGROUND: Fingolimod demonstrated superior efficacy compared with interferon β-1a intramuscular in relapsing multiple sclerosis. The impact of treatment history on fingolimod efficacy is unknown.OBJECTIVES: This post-hoc analysis of phase 3 TRANSFORMS data compared the efficacy and safety of fingolimod...

Cite
Khatri BO, Pelletier J, Kappos L, et al. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord. 2013;3(3):355-63doi: 10.1016/j.msard.2013.11.006.
Khatri, B. O., Pelletier, J., Kappos, L., Hartung, H. P., Comi, G., Barkhof, F., von Rosenstiel, P., Meng, X., Grinspan, A., Hashmonay, R., Cohen, J. A. (2014). Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Multiple sclerosis and related disorders, 3(3), 355-63. https://doi.org/10.1016/j.msard.2013.11.006
Khatri, B O, et al. "Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS)." Multiple sclerosis and related disorders vol. 3,3 (2014): 355-63. doi: https://doi.org/10.1016/j.msard.2013.11.006
Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12. PMID: 25876473.
Copy Download .nbib Format: NLM
A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical

Freedman MS, Wolinsky JS, Truffinet P, Comi G, Kappos L, Miller AE, Olsson TP, Benamor M, Chambers S, O'Connor PW.
PMID: 28607708
Mult Scler J Exp Transl Clin. 2015 Dec 07;1:2055217315618687. doi: 10.1177/2055217315618687. eCollection 2015.

BACKGROUND: Teriflunomide is a once-daily oral immunomodulator for the treatment of relapsing-remitting MS.OBJECTIVE: To evaluate the safety and tolerability of teriflunomide as add-on therapy to a stable dose of glatiramer acetate (GA) in patients with relapsing forms of MS...

Cite
Freedman MS, Wolinsky JS, Truffinet P, et al. A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis. Mult Scler J Exp Transl Clin. 2015;1:2055217315618687doi: 10.1177/2055217315618687.
Freedman, M. S., Wolinsky, J. S., Truffinet, P., Comi, G., Kappos, L., Miller, A. E., Olsson, T. P., Benamor, M., Chambers, S., & O'Connor, P. W. (2015). A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis. Multiple sclerosis journal - experimental, translational and clinical, 12055217315618687. https://doi.org/10.1177/2055217315618687
Freedman, M S, et al. "A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis." Multiple sclerosis journal - experimental, translational and clinical vol. 1 (2015): 2055217315618687. doi: https://doi.org/10.1177/2055217315618687
Freedman MS, Wolinsky JS, Truffinet P, Comi G, Kappos L, Miller AE, Olsson TP, Benamor M, Chambers S, O'Connor PW. A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis. Mult Scler J Exp Transl Clin. 2015 Dec 07;1:2055217315618687. doi: 10.1177/2055217315618687. eCollection 2015. PMID: 28607708; PMCID: PMC5433345.
Copy Download .nbib Format: NLM
A case of presumed herpes keratouveitis in a patient treated with fingolimod.

Multiple sclerosis journal - experimental, translational and clinical

Ayers MC, Conway DS.
PMID: 28607729
Mult Scler J Exp Transl Clin. 2016 Jun 03;2:2055217316652907. doi: 10.1177/2055217316652907. eCollection 2016.

We discuss a case of presumed bilateral herpes simplex keratouveitis in a 36-year-old multiple sclerosis patient switched to fingolimod from glatiramer acetate. Fingolimod treatment appears to increase the risk of herpesvirus infections, including with herpes simplex virus and varicella...

Cite
Ayers MC, Conway DS. A case of presumed herpes keratouveitis in a patient treated with fingolimod. Mult Scler J Exp Transl Clin. 2016;2:2055217316652907doi: 10.1177/2055217316652907.
Ayers, M. C., & Conway, D. S. (2016). A case of presumed herpes keratouveitis in a patient treated with fingolimod. Multiple sclerosis journal - experimental, translational and clinical, 22055217316652907. https://doi.org/10.1177/2055217316652907
Ayers, Malissa C, and Conway, Devon S. "A case of presumed herpes keratouveitis in a patient treated with fingolimod." Multiple sclerosis journal - experimental, translational and clinical vol. 2 (2016): 2055217316652907. doi: https://doi.org/10.1177/2055217316652907
Ayers MC, Conway DS. A case of presumed herpes keratouveitis in a patient treated with fingolimod. Mult Scler J Exp Transl Clin. 2016 Jun 03;2:2055217316652907. doi: 10.1177/2055217316652907. eCollection 2016. PMID: 28607729; PMCID: PMC5433502.
Copy Download .nbib Format: NLM
Persistence in Open and Closed Data Sources: A Study of Fingolimod Verse Interferons/Glatiramer Acetate in Patients with Multiple Sclerosis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Lahoz R, Bergvall N, Nazareth T, Korn JR.
PMID: 27200959
Value Health. 2014 Nov;17(7):A401. doi: 10.1016/j.jval.2014.08.913. Epub 2014 Oct 26.

No abstract available.

Cite
Lahoz R, Bergvall N, Nazareth T, et al. Persistence in Open and Closed Data Sources: A Study of Fingolimod Verse Interferons/Glatiramer Acetate in Patients with Multiple Sclerosis. Value Health. 2014;17(7):A401doi: 10.1016/j.jval.2014.08.913.
Lahoz, R., Bergvall, N., Nazareth, T., & Korn, J. R. (2014). Persistence in Open and Closed Data Sources: A Study of Fingolimod Verse Interferons/Glatiramer Acetate in Patients with Multiple Sclerosis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A401. https://doi.org/10.1016/j.jval.2014.08.913
Lahoz, R, et al. "Persistence in Open and Closed Data Sources: A Study of Fingolimod Verse Interferons/Glatiramer Acetate in Patients with Multiple Sclerosis." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A401. doi: https://doi.org/10.1016/j.jval.2014.08.913
Lahoz R, Bergvall N, Nazareth T, Korn JR. Persistence in Open and Closed Data Sources: A Study of Fingolimod Verse Interferons/Glatiramer Acetate in Patients with Multiple Sclerosis. Value Health. 2014 Nov;17(7):A401. doi: 10.1016/j.jval.2014.08.913. Epub 2014 Oct 26. PMID: 27200959.
Copy Download .nbib Format: NLM
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.

Frontiers in immunology

Claes N, Fraussen J, Stinissen P, Hupperts R, Somers V.
PMID: 26734009
Front Immunol. 2015 Dec 21;6:642. doi: 10.3389/fimmu.2015.00642. eCollection 2015.

Multiple sclerosis (MS) is a severe disease of the central nervous system (CNS) characterized by autoimmune inflammation and neurodegeneration. Historically, damage to the CNS was thought to be mediated predominantly by activated pro-inflammatory T cells. B cell involvement in...

Cite
Claes N, Fraussen J, Stinissen P, et al. B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol. 2015;6:642doi: 10.3389/fimmu.2015.00642.
Claes, N., Fraussen, J., Stinissen, P., Hupperts, R., & Somers, V. (2015). B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Frontiers in immunology, 6642. https://doi.org/10.3389/fimmu.2015.00642
Claes, Nele, et al. "B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions." Frontiers in immunology vol. 6 (2015): 642. doi: https://doi.org/10.3389/fimmu.2015.00642
Claes N, Fraussen J, Stinissen P, Hupperts R, Somers V. B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol. 2015 Dec 21;6:642. doi: 10.3389/fimmu.2015.00642. eCollection 2015. PMID: 26734009; PMCID: PMC4685142.
Copy Download .nbib Format: NLM
Multiple sclerosis: Five new things.

Neurology. Clinical practice

Nicholas JA, Boster AL, Racke MK.
PMID: 24175156
Neurol Clin Pract. 2013 Oct;3(5):404-412. doi: 10.1212/CPJ.0b013e3182a78f94.

Preliminary studies have suggested that a high salt diet may play a role in the development of autoimmune disease and possibly multiple sclerosis (MS). Promising clinical trial results for 2 new therapies for MS have been reported. Dimethyl fumarate,...

Cite
Nicholas JA, Boster AL, Racke MK. Multiple sclerosis: Five new things. Neurol Clin Pract. 2013;3(5):404-412doi: 10.1212/CPJ.0b013e3182a78f94.
Nicholas, J. A., Boster, A. L., & Racke, M. K. (2013). Multiple sclerosis: Five new things. Neurology. Clinical practice, 3(5), 404-412. https://doi.org/10.1212/CPJ.0b013e3182a78f94
Nicholas, Jacqueline A, et al. "Multiple sclerosis: Five new things." Neurology. Clinical practice vol. 3,5 (2013): 404-412. doi: https://doi.org/10.1212/CPJ.0b013e3182a78f94
Nicholas JA, Boster AL, Racke MK. Multiple sclerosis: Five new things. Neurol Clin Pract. 2013 Oct;3(5):404-412. doi: 10.1212/CPJ.0b013e3182a78f94. PMID: 24175156; PMCID: PMC3806932.
Copy Download .nbib Format: NLM
Glatiramer acetate in the treatment of multiple sclerosis.

Neuropsychiatric disease and treatment

Tselis A, Khan O, Lisak RP.
PMID: 19300558
Neuropsychiatr Dis Treat. 2007 Apr;3(2):259-67. doi: 10.2147/nedt.2007.3.2.259.

Glatiramer acetate is an immunomodulating drug used in the treatment of multiple sclerosis. It consists of a copolymer of amino acid residues in the same stoichiometric proportions as in myelin basic protein. Its mechanism of action is not entirely...

Cite
Tselis A, Khan O, Lisak RP. Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2007;3(2):259-67doi: 10.2147/nedt.2007.3.2.259.
Tselis, A., Khan, O., & Lisak, R. P. (2007). Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatric disease and treatment, 3(2), 259-67. https://doi.org/10.2147/nedt.2007.3.2.259
Tselis, Alex, et al. "Glatiramer acetate in the treatment of multiple sclerosis." Neuropsychiatric disease and treatment vol. 3,2 (2007): 259-67. doi: https://doi.org/10.2147/nedt.2007.3.2.259
Tselis A, Khan O, Lisak RP. Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2007 Apr;3(2):259-67. doi: 10.2147/nedt.2007.3.2.259. PMID: 19300558; PMCID: PMC2654627.
Copy Download .nbib Format: NLM
The relevance of animal models in multiple sclerosis research.

Pathophysiology : the official journal of the International Society for Pathophysiology

Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I.
PMID: 20537877
Pathophysiology. 2011 Feb;18(1):21-9. doi: 10.1016/j.pathophys.2010.04.004.

Multiple Sclerosis (MS) is a complex disease with an unknown etiology and no effective cure, despite decades of extensive research that led to the development of several partially effective treatments. Researchers have only limited access to early and immunologically...

Cite
Denic A, Johnson AJ, Bieber AJ, et al. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011;18(1):21-9doi: 10.1016/j.pathophys.2010.04.004.
Denic, A., Johnson, A. J., Bieber, A. J., Warrington, A. E., Rodriguez, M., & Pirko, I. (2011). The relevance of animal models in multiple sclerosis research. Pathophysiology : the official journal of the International Society for Pathophysiology, 18(1), 21-9. https://doi.org/10.1016/j.pathophys.2010.04.004
Denic, Aleksandar, et al. "The relevance of animal models in multiple sclerosis research." Pathophysiology : the official journal of the International Society for Pathophysiology vol. 18,1 (2011): 21-9. doi: https://doi.org/10.1016/j.pathophys.2010.04.004
Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011 Feb;18(1):21-9. doi: 10.1016/j.pathophys.2010.04.004. PMID: 20537877; PMCID: PMC3858209.
Copy Download .nbib Format: NLM
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.

Neuropsychiatric disease and treatment

Murphy JA, Harris JA, Crannage AJ.
PMID: 20957121
Neuropsychiatr Dis Treat. 2010 Oct 05;6:619-25. doi: 10.2147/NDT.S3501.

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab,...

Cite
Murphy JA, Harris JA, Crannage AJ. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2010;6:619-25doi: 10.2147/NDT.S3501.
Murphy, J. A., Harris, J. A., & Crannage, A. J. (2010). Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric disease and treatment, 6619-25. https://doi.org/10.2147/NDT.S3501
Murphy, Julie A, et al. "Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis." Neuropsychiatric disease and treatment vol. 6 (2010): 619-25. doi: https://doi.org/10.2147/NDT.S3501
Murphy JA, Harris JA, Crannage AJ. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2010 Oct 05;6:619-25. doi: 10.2147/NDT.S3501. PMID: 20957121; PMCID: PMC2951744.
Copy Download .nbib Format: NLM
The role of glatiramer acetate in the early treatment of multiple sclerosis.

Neuropsychiatric disease and treatment

Brandes DW.
PMID: 20628633
Neuropsychiatr Dis Treat. 2010 Jun 24;6:329-36. doi: 10.2147/ndt.s5898.

The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The...

Cite
Brandes DW. The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2010;6:329-36doi: 10.2147/ndt.s5898.
Brandes, D. W. (2010). The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatric disease and treatment, 6329-36. https://doi.org/10.2147/ndt.s5898
Brandes, David W. "The role of glatiramer acetate in the early treatment of multiple sclerosis." Neuropsychiatric disease and treatment vol. 6 (2010): 329-36. doi: https://doi.org/10.2147/ndt.s5898
Brandes DW. The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2010 Jun 24;6:329-36. doi: 10.2147/ndt.s5898. PMID: 20628633; PMCID: PMC2898171.
Copy Download .nbib Format: NLM
Assessing cost-effectiveness in the management of multiple sclerosis.

ClinicoEconomics and outcomes research : CEOR

Phillips CJ, Humphreys I.
PMID: 21935308
Clinicoecon Outcomes Res. 2009;1:61-78. doi: 10.2147/ceor.s4225. Epub 2009 Nov 18.

Multiple sclerosis (MS) is one of the most common causes of neurological disability in young and middle-aged adults, with current prevalence rates estimated to be 30 per 100,000 populations. Women are approximately twice as susceptible as males, but males...

Cite
Phillips CJ, Humphreys I. Assessing cost-effectiveness in the management of multiple sclerosis. Clinicoecon Outcomes Res. 2009;1:61-78doi: 10.2147/ceor.s4225.
Phillips, C. J., & Humphreys, I. (2009). Assessing cost-effectiveness in the management of multiple sclerosis. ClinicoEconomics and outcomes research : CEOR, 161-78. https://doi.org/10.2147/ceor.s4225
Phillips, Ceri J, and Humphreys, Ioan. "Assessing cost-effectiveness in the management of multiple sclerosis." ClinicoEconomics and outcomes research : CEOR vol. 1 (2009): 61-78. doi: https://doi.org/10.2147/ceor.s4225
Phillips CJ, Humphreys I. Assessing cost-effectiveness in the management of multiple sclerosis. Clinicoecon Outcomes Res. 2009;1:61-78. doi: 10.2147/ceor.s4225. Epub 2009 Nov 18. PMID: 21935308; PMCID: PMC3169986.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 300 entries